Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of R-CDOP in treatment-Naïve non-Hodgkin lymphoma with high tumor burden: A multicenter, prospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

WGWei GuoCLC S Liu

Discussion

Loading...

Member takes

Overview

Prospective trial shows R-CDOP improves progression-free survival in non-Hodgkin lymphoma, indicating safety and efficacy.

Key Points

  • This research aims to evaluate the efficacy and safety of R-CDOP in treatment-naïve non-Hodgkin lymphoma patients with high tumor burden.
  • Single-arm, multicenter, prospective trial
  • Patients with CD20+ diffuse large B-cell lymphoma or grade 3b follicular lymphoma
  • Treatment with R-CDOP every 21 days for 4 to 6 cycles
  • Endpoints include ORR, CRR, DCR, PFS, OS, and safety metrics
  • 86.4% objective response rate in efficacy-evaluable patients
  • 52.5% complete response rate
  • 93.2% disease control rate
  • Median progression-free survival not reached; 1-year PFS rate 75.8%
  • Most common grade 3/4 adverse events include neutropenia (17.2%) and anemia (14.1%)

Cite This Study

Guo et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d635https://doi.org/10.1182/blood-2025-1921
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Retrospective analysis of R-CDOP efficacy and safety in frail patients with DLBCL compared to R-CHOP in fit patients2025
  2. 2Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin’s lymphoma: A systematic review and meta-analysis2022 · 4 citations
  3. 3CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma2006 · 59 citations
  4. 4The efficacy and cardiac toxicity of different‐dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma2022 · 11 citations
  5. 5R-cmop and pola-R-CMP regimens as first-line treatment for diffuse large B-cell lymphoma with cardiac comorbidity: A prospective, single-arm, multicenter study2025